164 related articles for article (PubMed ID: 38619429)
1. mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes.
Jones AK; Bajrami B; Campbell MK; Erzurumluoglu AM; Guo Q; Chen H; Zhang X; Zeveleva S; Kvaskoff D; Brunner AD; Muller S; Gathey V; Dave RM; Tanner JW; Rixen S; Struwe MA; Phoenix K; Klumph KJ; Robinson H; Veyel D; Muller A; Noyvert B; Bartholdy BA; Steixner-Kumar AA; Stutzki J; Drichel D; Omland S; Sheehan R; Hill J; Bretschneider T; Gottschling D; Scheidig AJ; Clement B; Giera M; Ding Z; Broadwater J; Warren CR
Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38619429
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte mARC1 promotes fatty liver disease.
Lewis LC; Chen L; Hameed LS; Kitchen RR; Maroteau C; Nagarajan SR; Norlin J; Daly CE; Szczerbinska I; Hjuler ST; Patel R; Livingstone EJ; Durrant TN; Wondimu E; BasuRay S; Chandran A; Lee WH; Hu S; Gilboa B; Grandi ME; Toledo EM; Erikat AHA; Hodson L; Haynes WG; Pursell NW; Coppieters K; Fleckner J; Howson JMM; Andersen B; Ruby MA
JHEP Rep; 2023 May; 5(5):100693. PubMed ID: 37122688
[TBL] [Abstract][Full Text] [Related]
3. Liver-specific mitochondrial amidoxime-reducing component 1 (Mtarc1) knockdown protects the liver from diet-induced MASH in multiple mouse models.
Guo Y; Gao Z; LaGory EL; Kristin LW; Gupte J; Gong Y; Rardin MJ; Liu T; Nguyen TT; Long J; Hsu YH; Murray JK; Lade J; Jackson S; Zhang J
Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38696369
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome.
Dutta T; Sasidharan K; Ciociola E; Pennisi G; Noto FR; Kovooru L; Kroon T; Lindblom A; Du Y; Pirmoradian M; Wallin S; Mancina RM; Lindén D; Romeo S
Liver Int; 2024 May; 44(5):1219-1232. PubMed ID: 38375985
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and functional characterization of the p.A165T missense variant of mitochondrial amidoxime-reducing component 1.
Hou W; Watson C; Cecconie T; Bolaki MN; Brady JJ; Lu Q; Gatto GJ; Day TA
J Biol Chem; 2024 May; ():107353. PubMed ID: 38723751
[TBL] [Abstract][Full Text] [Related]
6. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of LCN13 through FXR activation ameliorates hepatocellular lipid accumulation and inflammation.
Qin X; Tan Y; Ren W; Zhou W; Niu R; Liang L; Li J; Cao K; Wei G; Zhu X; Huang M
Int Immunopharmacol; 2024 Apr; 131():111812. PubMed ID: 38493698
[TBL] [Abstract][Full Text] [Related]
8. Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse.
Smagris E; Shihanian LM; Mintah IJ; Bigdelou P; Livson Y; Brown H; Verweij N; Hunt C; Johnson RO; Greer TJ; Hartford SA; Hindy G; Sun L; Nielsen JB; Halasz G; Lotta LA; Murphy AJ; Sleeman MW; Gusarova V
PLoS Genet; 2024 Mar; 20(3):e1011179. PubMed ID: 38437227
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Human Hepatocyte Drug Metabolism Carrying High-Risk or Protection-Associated Liver Disease Genetic Variants.
Faccioli LAP; Cetin Z; Kocas-Kilicarslan ZN; Ortiz K; Sun Y; Hu Z; Kurihara T; Tafaleng EN; Florentino RM; Wang Z; Xia M; Miedel MT; Taylor DL; Behari J; Ostrowska A; Constantine R; Li A; Soto-Gutierrez A
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686209
[TBL] [Abstract][Full Text] [Related]
10. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.
Salvoza N; Giraudi P; Gazzin S; Bonazza D; Palmisano S; de Manzini N; Zanconati F; Raseni A; Sirianni F; Tiribelli C; Rosso N
J Transl Med; 2023 Dec; 21(1):906. PubMed ID: 38082368
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte Deubiquitinating Enzyme OTUD5 Deficiency is a Key Aggravator for Metabolic Dysfunction-Associated Steatohepatitis by Disturbing Mitochondrial Homeostasis.
Dai J; Zhang L; Zhang R; Ge J; Yao F; Zhou S; Xu J; Yu K; Xu J; Jiang L; Jin K; Dai X; Li J; Li Q
Cell Mol Gastroenterol Hepatol; 2024; 17(3):399-421. PubMed ID: 38036082
[TBL] [Abstract][Full Text] [Related]
12. Protective hepatocyte signals restrain liver fibrosis in metabolic dysfunction-associated steatohepatitis.
Steffani M; Geng Y; Pajvani UB; Schwabe RF
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557494
[TBL] [Abstract][Full Text] [Related]
13. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
[TBL] [Abstract][Full Text] [Related]
14. Loss of mitochondrial adaptation associates with deterioration of mitochondrial turnover and structure in metabolic dysfunction-associated steatotic liver disease.
Sarabhai T; Kahl S; Gancheva S; Mastrototaro L; Dewidar B; Pesta D; Ratter-Rieck JM; Bobrov P; Jeruschke K; Esposito I; Schlensak M; Roden M
Metabolism; 2024 Feb; 151():155762. PubMed ID: 38122893
[TBL] [Abstract][Full Text] [Related]
15. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Backer S; Khanna D
Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
[TBL] [Abstract][Full Text] [Related]
16. The mitochondrial amidoxime-reducing component (mARC1) is a novel signal-anchored protein of the outer mitochondrial membrane.
Klein JM; Busch JD; Potting C; Baker MJ; Langer T; Schwarz G
J Biol Chem; 2012 Dec; 287(51):42795-803. PubMed ID: 23086957
[TBL] [Abstract][Full Text] [Related]
17. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
18. Fatty liver disease protective MTARC1 p.A165T variant reduces the protein stability of MTARC1.
Wu M; Tie M; Hu L; Yang Y; Chen Y; Ferguson D; Chen Y; He A
Biochem Biophys Res Commun; 2024 Apr; 702():149655. PubMed ID: 38340654
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomics-driven metabolic pathway analysis reveals similar alterations in lipid metabolism in mouse MASH model and human.
Tsouka S; Kumar P; Seubnooch P; Freiburghaus K; St-Pierre M; Dufour JF; Masoodi M
Commun Med (Lond); 2024 Mar; 4(1):39. PubMed ID: 38443644
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASH.
Cano L; Desquilles L; Ghukasyan G; Angenard G; Landreau C; Corlu A; Clément B; Turlin B; Le Ferrec E; Aninat C; Massart J; Musso O
JHEP Rep; 2024 Jan; 6(1):100936. PubMed ID: 38074511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
